top of page

SUBSCRIBE TO OUR NEWSLETTER

SMART STUDY DESIGNS FOR STRATEGIC CLINICAL TRIALS

MEDSIR-LED CLINICAL TRIALS IN ONCOLOGY UNITE SCIENTIFIC EXCELLENCE, PATIENT FOCUS AND STRATEGIC THINKING. MEDSIR MANAGEMENT MODEL ENSURES SPEED, RELIABILITY, AND THE STREAMLINING OF CLINICAL DEVELOPMENT PLANS.

WE STRIVE TO IMPROVE THE LIVES OF ALL PATIENTS WITH CANCER

The MEDSIR concept of providing a platform to facilitate the development of ideas into strategic clinical study protocols is becoming more diverse, incorporating not only new tumor types, but also modern and innovative trial designs such as umbrella and multi-tumor basket trials.

Working on a new clinical project with the expectation that it will help many patients is exhilarating for MEDSIR, a job well done means results that have the potential to change clinical practice. Here you will find our comprehensive project portfolio.

Please contact us for further information.

“LET´S CONVERT YOUR RESEARCH IDEA INTO A BRIGHTER FUTURE FOR CANCER PATIENTS”

MEDSIR'S CLINICAL TRIALS AND STUDIES

ABIGAIL

BREAST

Abemaciclib with endocrine therapy ± paclitaxel in aggressive ER+/HER2- advanced breast cancer

ATractiB

BREAST

First-line atezolizumab with paclitaxel and bevacizumab for advanced or metastatic TNBC

BRIDGE

LUNG

Durvalumab and chemotherapy induction followed by durvalumab and radiotherapy in large volume stage III NSCLC

COPÉRNICO

COVID-19

Tocilizumab with pembrolizumab for treatment of COVID-19 pneumonia in patients unresponsive to standard care

EMPRESS

BREAST

Giredestrant (GDC-9545) or Tamoxifen in ER+/HER2- Ki67≥10% Early Breast Cancer

LINGain

BREAST

Sub-study of predictive immunogenicity biomakers for target therapy in HER2+ early breast cancer

METALLICA

BREAST

Metformin to prevent hyperglycemia in HR+/HER- PI3KCA-mutated advanced breast cancer patients treated with alpelisib and endocrine therapy

OPHELIA

BREAST

Olaparib plus Trastuzumab for HER2+, BRCA Mutated or HRD Advanced Breast Cancer

PARSIFAL-LONG

BREAST

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

PHERGAIN

BREAST

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: A FDG-PET response-adapted strategy

POLTER

BREAST

Optimization of balixafortide with nab-paclitaxel or eribulin for HER2- advanced breast cancer

REVERT

BREAST

Eribulin monotherapy or eribulin plus endocrine therapy in locally-recurrent or metastatic breast cancer patients after progression on endocrine therapy

THELMA

BREAST

Trastuzumab emtansine (TDM1) with non pegylated liposomal doxorubicin in HER2+ metastic breast cancer

TUXEDO-4

BREAST

Trastuzumab-deruxtecan in HER2-low breast cancer with newly diagnosed or progressing brain metastases

ADELA

BREAST

Elacestrant + everolimus in patients with ER+/HER2-, esr1mut, advanced breast cancer progressing on endocrine therapy and CDK4/6 inhibitors

AZENT

LUNG

Osimertinib in First-line Locally Advanced or Metastatic NSCLC Patients With EGFR and EGFR T790M

BioPER

BREAST

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ metastatic breast cancer

DEBBRAH

BREAST

Trastuzumab deruxtecan in HER2+ advance breast cancer with brain mets and/or leptomeningeal carcinomatosis

EXCAAPE

PROSTATE

Evaluation of Rad-223 Activity in Asymptomatic Patients With mCRPC While on Abiraterone or Enzalutamide Besides AR-V7 Status

LUPER

LUNG

Lurbinectedin with Pembrolizumab in relaspsed small cell lung cancer

MIRADOR

BREAST

Monitoring Minimal Residual Disease Using ctDNA in HR+/HER2- early breast cancer

ORPHEUS

PENIS

Phase II Study of the Efficacy of INCMGA00012 in Penile Squamous Cell Carcinoma

PATHFINDER

BREAST

Ipatasertib with non-taxane chemotherapy for taxane-pretreated unresectable locally advanced or metastatic TNBC

PHERGAIN-2

BREAST

Trastuzumab, pertuzumab and TDM1 for HER2+ early breast cancer

PQR309-007

BREAST

PQR309 and eribulin for locally advanced or metastatic HER- and TNBC

ROSHER

BREAST

Real-World Data of Clinicopathological Characteristics and Management of Patients With HER2+ Breast Cancer

TRANSFAL

BREAST

Sub-study of predictive biomarkers for palbociclib and endocrine therapy in ER+/HER2- advanced breast cancer

ZZFIRST

PROSTATE

Enzalutamide Plus Talazoparib for the Treatment of Hormone Sensitive Prostate Cancer

ASUNCTIS

COVID-19

Open label trial of Asunercept for severe COVID-19 disease

BARBICAN

BREAST

Evaluation of ipatasertib added to combination of neoadjuvant chemotherapy and atezolizumab in women with TNBC

CAILA

BREAST

CB-103 plus NSAI and letrozole or anastrozole in luminal advanced breast cancer

DEMETHER

BREAST

PHESGO Maintenance After T-DXd Short Induction for HER2+ Unresectable Locally Recurrent or Metastatic Breast Cancer

I3LUNG

LUNG

Integrative science, Intelligent data platform for Individualized LUNG cancer care with Immunotherapy

LUZERN

BREAST

Niraparib plus Aromatase Inhibitors for Luminal-like and gBRCA or HRD-positive Metastatic Breast Cancer

NOBROLA

BREAST

A Two-stage Simon Design Phase II Study of Single Agent Olaparib for Non-BRCA MBC Patients With HRD

PALMIRA

BREAST

Palbociclib with second-line endocrine therapy for HR+/HER2- Advanced Breast Cancer patients who had a clinical benefit during first-line palbociclib-based...

PECATI

THYMIC

Phase II study of the combination of Pembrolizumab and Lenvatinib in pre-treated thymic carcinoma

POEM

ENDOMETRIUM

Identification of endometrial cacinoma biomarkers associated with a short term exposure to temsirolimus

PRIMED

BREAST

Multicenter, Open-label, Single arm, Phase II Clinical Trial to Improve Sacituzumab Govitecan Tolerance in Patients with Metastatic Triple-Negative Breast Cancer

SABINA

BREAST

MEN1611 monotherapy or in combination with eribulin for PIK3CA/PTEN altered metaplastic breast cancer

TRASTYVERE

BREAST

Clinical benefit of trastuzumab with lapatinib in HER2+ breast cancer previously treated with trastuzumab and/or lapatinib

ATHENA

BREAST

Bevacizumab plus chemotherapy in locally recurrent or metastatic breast cancer

BIOPER

BREAST

Molecular Mechanisms of Resistance and Sensitivity to Palbociclib Re-challenge in ER+ metastatic breast cancer

CALADRIO

BREAST

Prospective evaluation of microbiome as a potential predictive factor for immunotherapy in luminal-like breast cancer within the KELLY clinical study

DxCARTES

BREAST

Neoadjuvant Letrozole and Palbociclib in Patients With Stage II-IIIB HR+, HER2- Breast Cancer

KELLY

BREAST

Pembrolizumab and eribulin for HR+/HER- metastatic breast cancer previously treated with antracyclines and taxanes

MERIBEL

BREAST

First Line Eribulin monotherapy In HER2- Metastatic Breast Cancer

NSABP FB-7

BREAST

Neoadjuvant therapy with weekly (1) paclitaxel and neratinib, or (2) trastuzumab and paclitaxel, or (3) neratinib, trastuzumab, and paclitaxel, followed by...

PARSIFAL

BREAST

Palbociclib with fulvestrant or letrozole for HER-, ER+ metastatic breast cancer

PHENOMENAL

BREAST

Nal-iri for progressing brain mets in patients with HER2- breast cancer

POLEN

ENDOMETRIUM

Biomarker changes associated to short exposure to olaparib as potential predictors in Endometrial Carcinoma

REPOSE

LUNG

REPotrectinib in ROS1-positive Non-small Cell Lung Cancer Patients With Active Brain mEtastasis

SLLIP

LUNG

Spanish lung liquid vs. invasive biopsy program evaluation.

TUXEDO-3

BREAST-LUNG

Partritumab deruxtecan in patients with active brain mets from mBC and NCSLC, and leptomeningeal carcinomatosis from advanced solid tumors

"

WE TURN THE BEST CLINICAL RESEARCH IDEAS INTO A BRIGHTER FUTURE FOR CANCER PATIENTS.

bottom of page